Wet AMD sufferers unaware of pre-existing AMD

Article

Current screening of patients with age-related macular degeneration (AMD) does not sufficiently identify those patients most at risk of wet AMD and hence is unable to prevent its development, according to a report published in the June 2008 issue of Eye.

Current screening of patients with age-related macular degeneration (AMD) does not sufficiently identify those patients most at risk of wet AMD and hence is unable to prevent its development, according to a report published in the June 2008 issue of Eye.

Itay Chowers, MD of the Hadassah-Hebrew University Medical Center, Israel and colleagues conducted a retrospective analysis of NVAMD subjects (n=268) and compared characteristics between those subjects who were aware of their AMD before the NVAMD diagnosis (n=83), and those who were not (n=185).

The researchers found that there were no significant differences between the two groups in terms of demographic characteristics, visual acuity, lesion size and lesion composition. Patients who were not previously aware of their AMD were more likely to have a history of smoking (41%) than those who were aware (26%); patients with a positive family history of AMD were more likely to be aware of their own AMD before the NVAMD diagnosis (20%) than those who did not (10%).

The team concluded that the majority of patients receiving an NVAMD diagnosis were previously unaware that they had AMD, although early AMD detection may not entail detection of treatable choroidal neovascularization lesions.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.